Respiratory Syncytial Virus (RSV) Detection Among Adults With Underlying Cardiopulmonary Disease Hospitalized With Acute Respiratory Illness
Negar Aliabadi(Pfizer (United States)), Elizabeth Begier(Pfizer (United States)), Sheetal Uppal(Pfizer (United States)), Thomas Chandler(Norton Healthcare), Paula Peyrani(University of Louisville), Alan D. Junkins(Norton Healthcare), Eduardo Gonzalez(Pfizer (United States)), Zibiao Zhong(Wuhan University), Samira Mubareka(Sunnybrook Health Science Centre), Julio A. Ramírez(Norton Healthcare), Malak Elsobky(Pfizer (United States)), Paul E. Schulz(The University of Texas Health Science Center at Houston), Bradford D. Gessner(Pfizer (United States)), Kari Yacisin(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), Luis Jódar(Pfizer (United States)), Ruth Carrico(Norton Healthcare), Edward E. Walsh(University of Rochester), Stephen Furmanek(Norton Healthcare), C. Vermeiren, Ann R. Falsey(University of Rochester), C. Kassee(Sinai Health System), Qing Liu(Hong Kong Polytechnic University), Kevin Katz, Arthur A.M. Wilde(Amsterdam Neuroscience), Robin Hubler(Pfizer (United States)), Allison McGeer(Sinai Hospital)
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
The Global Burden of Cancer 2013
|JAMA Oncology|2015|2.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
|New England Journal of Medicine|2005|2.2k